Lars Birgerson

Lars Birgerson

Company: Adlai Nortye

Job title: Chief Executive Officer

Seminars:

The BURAN Study of Buparlisib (AN2025) in Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma 10:15 am

Buparlisib (AN2025) is a 2,6-dimorpholino pyrimidine derivative oral pan-class I PI3K inhibitor. The PI3K signaling pathway is one of the most frequently altered pathways in HNSCC Results suggest that buparlisib in combination with paclitaxel could be an effective treatment following the failure of platinum-based chemotherapyRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.